Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Koch's Disease

imatinib mesylate has been researched along with Koch's Disease in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Huang, XP; Luo, ZB; Ouyang, GF; Xu, N1
De La Mora-Levy, JG; Hernández-Guerrero, AI; Jáquez-Quintana, JO; Rodríguez-Pendás, F1
Batinica, M; Brachvogel, B; Bruns, H; de Castro Kroner, J; Fabri, M; Hartmann, P; Inkeles, MS; Kalscheuer, R; Kröll, P; Modlin, RL; Pellegrini, M; Pitzler, L; Plum, G; Realegeno, S; Sommer, A; Steiger, J; Stenger, S; Stephan, A1
Daniels, JM; Janssen, JJ; Postmus, PE; van Altena, R; Vonk-Noordegraaf, A1
Bornmann, W; Cheruvu, M; Kalman, D; Napier, RJ; Powell, KR; Rafi, W; Salgame, P; Shinnick, TM; Zaunbrecher, MA1

Other Studies

5 other study(ies) available for imatinib mesylate and Koch's Disease

ArticleYear
Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection.
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2017, 12-01, Volume: 34, Issue:4

    Topics: China; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Interstitial; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Tuberculosis

2017
Endoscopic management of esophago-mediastinal fistula secondary to mediastinal tuberculosis infection.
    Gastrointestinal endoscopy, 2015, Volume: 82, Issue:2

    Topics: Antineoplastic Agents; Esophageal Fistula; Esophagoscopy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mediastinal Diseases; Mediastinitis; Middle Aged; Radiography; Stents; Tuberculosis

2015
Imatinib Triggers Phagolysosome Acidification and Antimicrobial Activity against Mycobacterium bovis Bacille Calmette-Guérin in Glucocorticoid-Treated Human Macrophages.
    Journal of immunology (Baltimore, Md. : 1950), 2016, 07-01, Volume: 197, Issue:1

    Topics: Anti-Inflammatory Agents; Antimicrobial Cationic Peptides; Antitubercular Agents; Autophagy; Cathelicidins; Cells, Cultured; Gene Expression Regulation; Glucocorticoids; Humans; Hydrogen-Ion Concentration; Imatinib Mesylate; Immunity, Innate; Interferon-gamma; Macrophages; Mycobacterium bovis; Phagosomes; Tuberculosis; Vacuolar Proton-Translocating ATPases

2016
Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia.
    The European respiratory journal, 2009, Volume: 33, Issue:3

    Topics: Adult; Antineoplastic Agents; Antitubercular Agents; Benzamides; CD8-Positive T-Lymphocytes; Humans; Imatinib Mesylate; Immune System; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mycobacterium tuberculosis; Piperazines; Pyrimidines; Signal Transduction; Treatment Outcome; Tuberculosis

2009
Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis.
    Cell host & microbe, 2011, Nov-17, Volume: 10, Issue:5

    Topics: Animals; Antitubercular Agents; Bacterial Proteins; Benzamides; Cell Line; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tuberculosis; Virulence

2011